NRXP amends $11M convertible note; $1.1M cash due Feb 12, then $400K/month through July

NRX Pharmaceuticals, Inc.

Third Amendment to $11.02M convertible note with Streeterville Capital executed Feb 9, 2024.
Company to pay $1.1M cash on Feb 12, 2024; monthly $400K cash minimum from Feb 29 to July 31, 2024.
During first three months, Streeterville cannot redeem above monthly minimum; after, up to $1M/month subject to cap.
Company can pay monthly minimum in shares if Streeterville submits redemption notices; otherwise cash required.
Outstanding balance after July 31, 2024 must be fully paid in cash by Aug 31, 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NRX Pharmaceuticals, Inc. amended Amendment #3 to Convertible Promissory Note with Streeterville Capital, LLC valued at $1,100,000 (effective 2024-02-09).

Action: amendment
Counterparty: Streeterville Capital, LLC
Value: $1,100,000
Effective: 2024-02-09

Exact text from the filing

On February 9, 2024 NRX Pharmaceuticals, Inc. (the “Company”) entered into Amendment #3 to Convertible Promissory Note (the “Third Amendment”), with Streeterville Capital, LLC (“Streeterville”).

View on SEC.gov

Browse all material agreements →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-023806

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.